Intravesical cisplatin for superficial bladder tumors Academic Article Article uri icon


MeSH Major

  • Bronchi
  • Carcinoma, Non-Small-Cell Lung
  • Epithelial Cells
  • Gene Expression Regulation, Neoplastic
  • Lung Neoplasms
  • NF-kappa B


  • Cisplatin, 50-150 mg in a maximum concentration of 1 mg/ml, was administered intravesically each week to 24 patients with multiple, recurrent carcinoma in situ and/or bladder tumors confined to the mucosa and lamina propria. All patients had a history of multiple transurethral resections and four had received prior chemotherapy. Response was evaluated by urinary cytology, cystoscopy, and biopsy. In a total of 237 weekly doses, toxicities included mild dysuria, pruritus, rash and in one patient, acute anaphylaxis. Only three (13%) patients were classified as achieving complete remission. Cisplatin, in the dose and schedule employed, is ineffective in controlling superficial bladder cancer.

publication date

  • January 1982



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19820901)50:5<863::AID-CNCR2820500509>3.0.CO;2-Q

PubMed ID

  • 7201343

Additional Document Info

start page

  • 863

end page

  • 5


  • 50


  • 5